ArticleFrontiers in immunology2025
Hypercholesterolemia and the role of lipid metabolism gene CES1 in immune infiltration promote central nervous system relapse in acute myeloid leukemia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A malignant symbiosis: The neuro-metabolic symphony rewires the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Review
- Cholesterol Reprogramming in Acute Myeloid Leukemia: Integrating Tumor-Intrinsic Metabolism and Immune Crosstalk.Diseases (Basel, Switzerland) · 2026Review
- Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alterations in multiple lipid metabolism pathways are associated with cancer progression. However, the relationship between lipid metabolism and central nervous system (CNS) relapse in acute myeloid leukemia (AML) remains unclear. Methods: We conducted a retrospective analysis of 806 AML cases to evaluate the association between serum lipid levels and the risk of CNS relapse. Additionally, RNA-sequencing data from 895 AML patients were obtained from the TARGET database to identify hub lipid metabolism-related genes (LMRGs) associated with CNS relapse. Results: Patients with CNS relapse exhibited significantly elevated levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) compared to the non-CNS relapse group. Hypercholesterolemia was identified as a risk factor for CNS relapse. RNA sequencing of AML patients with or without CNS relapse revealed 1,368 differentially expressed genes (DEGs). Functional enrichment analysis of the DEGs indicated a connection between lipid metabolism and CNS relapse. Through integrating these DEGs, LMRGs, and whole-genome correlation network analysis (WGCNA), carboxysterase 1 (CES1) was identified as a hub LMRG. High CES1 expression was a risk factor for CNS relapse and shorter overall survival. Moreover, CES1 influenced the proportion of nine types of tumor-infiltrating immune cells (TICs), particularly M2 macrophages, as supported by functional studies involving CES1 knockdown and overexpression in AML cells and AML xenograft tumor models. Conclusion: Hypercholesterolemia and CES1 can promote CNS relapse in AML patients, particularly through CES1's potential role in modulating immune infiltration within the TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.